Kathryn Skelding

Kathryn Skelding

Resume

Dr Kathryn Skelding is a tenured senior lecturer in the School of Biomedical Sciences and Pharmacy at the University of Newcastle, and leads the Cancer Cell Biology group. She obtained her BBiomedSci (Hons I) and PhD (in 2008) from the University of Newcastle. Dr Skelding has over 13 years experience in the pre-clinical evaluation of novel anti-cancer drugs (one of which is about to enter Phase III clinical trials), and she has received several awards throughout her research career, including the Newcastle Innovation Excellence in Innovation Award (2015), and the HCRA Excellence in Translational Research Award (2014). Her research focuses on examining signal transduction pathways and the role of protein-protein interactions (PPI) in regulating cancer cell proliferation, metastasis and chemotherapy resistance, so that new anti-cancer targets can be identified. Her laboratory has recently identified new pathways involved in these processes, and she has developed novel PPI inhibitors that can selectively target cancer cells. Dr Skelding’s laboratory is currently examining the pre-clinical efficacy of these new drugs in a range of cancer types, including acute myeloid and lymphoblastic leukaemia, glioblastoma, and breast cancer.